Genflow Biosciences PLC Announces Total Voting Rights
-
Iceland in suspense after close EU vote
-
Djokovic 'prepared' for US Open bid for history
-
Wallabies hold on for victory in Argentina
-
Atletico down Sevilla to go top of La Liga
-
Juve notch second straight win, Fiorentina's centenary party falls flat
-
US deports right-wing provocateur Milo Yiannopoulos
-
Rybakina eases injury fears ahead of US Open
-
Niger junta says it is back in control after soldiers' mutiny
-
Djokovic kicks off latest Grand Slam quest under US Open lights
-
Erasmus calls Rennie barbs over Springbok scrumming 'nonsense'
-
'Sorry' De Zerbi won't panic after Spurs shambles
-
Lawrence's fifty leaves Pakistan facing record chase to level England series
-
UN, Nepal warn of climate threat after deadly floods
-
Netanyahu condemns settler attack in flashpoint West Bank village
-
USTA boss says structure of new player council not yet set
-
Munoz saves Iraola in Liverpool draw, big-spending Spurs lose again
-
Tiny Elversberg stun Leverkusen on Bundesliga debut, Dortmund beat Hamburg
-
Newcastle condemn dismal Spurs to second successive defeat
-
About 50 Karnataka travellers return from Nepal as 24 remain missing
-
Five college football games that could shape the 2026 season
-
Editorial questions Letitia James’ record as New York attorney general
-
New finds strengthen case for Bethsaida at Sea of Galilee site
-
Los Angeles triplets weigh 19.3 pounds in unusually heavy birth
-
Felony assaults on older New Yorkers rise sharply, police data show
-
Matt Leinart assesses Arch Manning and the leading names in college football
-
Three Texas Tech softball players hurt in jet ski collision
-
Rural Tamil Nadu students present 64 technology projects at IIT-M research park
-
Tambaram civic groups seek action on eight long-pending issues
-
Tamil Nadu goalball team’s national silver highlights need for wider support
-
Chennai councillors unite across parties to demand ward development funds
-
Tamil Nadu and NUS agree to expand postgraduate and research links
-
Court orders JIPMER assessment of Durai Dayanidhi before money-laundering trial
-
India and China have not named two new border meeting sites
-
Kolkata police register new FIR against Mamata Banerjee over rally timing
-
James Cleverly leaves shadow cabinet to seek London mayoralty
-
Andhra Pradesh Speaker seeks stronger sports quota and school facilities
-
Cyberabad civic body demolishes 19 unauthorised structures
-
Chembur man held over alleged poisoning of woman’s soft drink
-
Chinchpoklicha Chintamani begins 2026 arrival procession in Parel
-
BMC rejects negligence claims in three Rajawadi Hospital maternity cases
-
Ankle ligament tear ends Neeraj Chopra’s 2026 season
-
Dolly Parton’s Imagination Library leaves global children’s reading legacy
-
Thirty-seven Mumbai pilgrims return after Nepal flood disruption
-
Family searches for Boston engineer missing after Nepal-Tibet floods
-
Baladi Map app turns Lebanon’s local problems into a public record
-
Police appeal for footage after life-threatening Stratford assault
-
French campaign sharpens as far right accuses left over civil disobedience calls
-
In London, son's agonising wait for news of parents missing in Nepal-Tibet floods
-
Norway's King Haakon VIII pays tribute to late father in first speech
-
Ivory Coast captain Kessie snubs Juventus to rejoin Atalanta
Genflow Biosciences PLC Announces Total Voting Rights
LONDON, UK / ACCESS Newswire / October 31, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases, announces that the total issued share capital of the Company as at 31 October 2025 consists of 493,547,942 Ordinary Shares none of which are held in treasury. Therefore, the total number of voting rights in the Company is 493,547,942.
The figure of 493,547,942 Ordinary Shares may be used by shareholders of the Company as the denominator for the calculations by which they will determine if they are required to notify their investment in, or a change in their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
Contacts
Genflow Biosciences | Harbor Access |
Dr Eric Leire, CEO | Jonathan Paterson, Investor Relations |
+32-477-495-881 | +1 475 477 9401 |
About Genflow Biosciences
Founded in 2020, Genflow Biosciences Plc. (LSE:GENF)(OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising results. Genflow's 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs planned include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there are no effective treatments. Please visit www.genflowbio.com and follow the Company on LinkedIn and X.
-Ends-
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
SOURCE: Genflow Biosciences PLC
View the original press release on ACCESS Newswire
A.Moore--AT
